Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...

Germany: A retrospective cohort study has found that prior use of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM) ...

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, ...

Empowering choice in the pharmacological management of type 2 diabetes One in nine people worldwide lives with diabetes, with 90% affected by type 2 diabetes.1 Despite ongoing advances in therapy and ...

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.

Early combination therapy could translate into fewer downstream hospitalizations and lower costs associated with dialysis and cardiovascular complications.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Mineralys Therapeutics Inc (MLYS) showcases promising trial results and strategic initiatives amid financial challenges and competitive pressures.

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...